Rapid HIV testing enables HIV prevention and care services to expand to settings with limited laboratory infrastructure. The World Health Organization recommends that prior to their implementation, rapid HIV tests first be evaluated at a reference laboratory and then at points-of-service, and that measures to ensure quality of testing be in place. We describe the experience of 11 African countries that implemented rapid HIV testing using this process. A questionnaire regarding rapid test evaluations and quality assurance measures was administered to personnel in ministries of health, reference laboratories, and Centers for Disease Control and Prevention programs in 11 African countries. In reference laboratory evaluations, median sensitivity was above 99% for 10 of 15 rapid tests and median specificity was above 99% for 13 of 15 rapid tests. Similar results were observed in evaluations at point-of-service sites. Rapid testing algorithms have been implemented in over 600 sites in nine of the countries. Concordance between point-of-service rapid testing and reference laboratory retesting of samples ranged from 95.7% to 99.5% (median: 98.7%). A systematic approach to the evaluation and implementation of rapid HIV tests was useful in ensuring accurate, decentralized testing even when conducted by persons with limited laboratory experience. 1491 
INTRODUCTION
A N ESTIMATED 34 TO 46 MILLION PEOPLE are living with HIV infection worldwide, and AIDS has become the leading cause of death among young adults globally. 1 To help mitigate this catastrophe, HIV prevention and treatment services are being enhanced through major initiatives such as the Global Fund for AIDS, Tuberculosis, and Malaria; the World Health Organization's Three by Five Initiative; and the U.S. government's Emergency Plan for AIDS Relief.
To achieve the ambitious goals of these initiatives, millions of persons will require HIV testing in order to appropriately target HIV prevention interventions and to identify individuals who need HIV care. 2, 3 However, the availability of HIV testing services is limited in many of the countries most affected by HIV due to a lack of laboratory facilities, trained personnel, equipment, and reagents. The development of rapid HIV tests has greatly extended the accessibility of HIV testing since they provide results within 30 min and can be performed with minimal equipment and training. [4] [5] [6] [7] Although evaluations conducted in resource-constrained countries have demonstrated that rapid HIV tests perform well in research settings, their performance may differ when used on a wide scale due to a lack of trained staff, poor laboratory infrastructure, and weak quality assurance programs. [8] [9] [10] In addition, the sensitivity of these tests for different subtypes, given the great genetic diversity of HIV-1 in Africa, is not well established. To help ensure rapid tests function as expected in settings of their intended use, the World Health Organization (WHO) has developed guidelines for country-based evaluation and implementation of rapid HIV testing. 11 These guidelines recommend a three-phase approach (Fig. 1) . In phase 1, candidate rapid HIV tests are evaluated for sensitivity and specificity in a reference laboratory. Tests that demonstrate acceptable performance are selected for phase 2, the field evaluation, which assesses the performance of rapid tests singly or in combination testing algorithms at point-of-service (POS) sites under the conditions of intended use. Based on the evaluation results, a rapid HIV testing algorithm is constructed using two or three rapid tests that fulfill the selection and performance require-ments. 12 The WHO guidelines advocate implementation of the algorithm with a system of continuous quality assurance (phase 3) that optimally includes training, supervision, and competency assessment of personnel who perform the tests; site visits to observe testing; and external quality assurance based on retesting a proportion of specimens by reference laboratories. 11 To date, only limited published data have described the utility of this approach for wide-scale rapid test implementation. We undertook this study to describe the experience with rapid test evaluation and implementation in 11 African countries.
MATERIALS AND METHODS
The Global AIDS Program (GAP) of the U.S. Centers for Disease Control and Prevention (CDC) is one of the agencies implementing the U.S. government's Emergency Plan for AIDS Relief. 13 GAP staff stationed in 25 resource-constrained countries work with host governments and with other public and private partners to support efforts to prevent HIV infections and build capacity to improve care and support. A critical component of most GAP country programs is the strengthening of na- tional laboratory capacity, including providing technical assistance for rapid HIV test evaluation and implementation. We identified 13 countries with a GAP country program in which evaluations of commercially available rapid HIV tests had been conducted within the past 5 years. In each country, GAP staff contacted persons who were involved in the evaluation activities including personnel from GAP country programs, reference laboratories, ministries of health, and other partner organizations. These persons formed the Rapid HIV Test Evaluation Working Group, which approved the project protocol and gave permission to publish evaluation results. Two countries chose not to participate because they were conducting updated rapid test evaluations and did not want to publish the results of earlier evaluations.
Collaborators in each country completed a standardized questionnaire about evaluation methods, test performance, algorithm development, implementation, and measures used to ensure quality of testing. Additional information about evaluation methods and outcomes was obtained from country reports, presentations, and other documentation. Data were entered and analyzed using Microsoft Excel (Microsoft Corporation, Redmond, WA) and SPSS (SPSS Inc., Chicago, IL). Results for three rapid tests that are no longer commercially available were excluded. The analysis was subdivided into the three evaluation phases (Fig. 1) . For each phase, evaluation methods and outcomes are presented.
The project was exempted from review by the CDC Institutional Review Board because it did not involve interaction with identifiable human subjects. 14, 15 The use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Service or the US Department of Health and Human Services. In Kenya and Zimbabwe, rapid HIV tests were evaluated individually. In the remaining eight countries, a median of five (range: three to nine) tests was evaluated simultaneously. Evaluations were conducted in a national reference laboratory or hospital laboratory by experienced laboratory personnel who had received training in conducting rapid tests. Specimens were obtained from one or more sources including hospitals or clinics, research studies, blood donation centers, and voluntary counseling and testing (VCT) centers. Half of the evaluations used previously collected stored serum or plasma specimens and half used prospectively collected whole blood, serum, or plasma specimens. Capillus, Determine, Hema-Strip, OraQuick, and UniGold were each included in at least three retrospective evaluations that used stored specimens and at least three evaluations that used prospectively collected specimens.
RESULTS

Reference
The rapid test result for each specimen was compared with the result from the nationally approved HIV testing algorithm. In five countries, these gold standard algorithms involved parallel enzyme immunoassays (EIAs) in which each specimen was tested with two different EIAs. Discordant results were resolved with Western blot (WB) in three of the five countries, with repeat EIA testing in one country, and with a third, different EIA in one country. In four countries, the gold standard algorithms involved serial EIAs in which a second, different EIA was used only if the first EIA was positive. Discordant results were resolved with WB in three of the four countries and with repeat EIA testing in one country. Finally, WB served as the reference test in one country; specimens with indeterminate results were excluded.
Evaluation outcomes. Evaluations tested a median of 506 (range: 51-2000) specimens, of which a median of 38% (range: 14-78%) were HIV positive. We present the median and range of sensitivity and specificity for each rapid test based on performance in one or more evaluations (Table 2) . Median sensitivity ranged from 92.5% to 100% and exceeded 99% for 10 of the 15 tests. Median specificity ranged from 97.4% to 100% and exceeded 99% for 13 of the 15 tests. Nine of the 15 rapid tests demonstrated a sensitivity or specificity below 99% in at least one evaluation. Median sensitivity and specificity for Capillus, Determine, Hema-Strip, OraQuick, and Unigold were similar in the retrospective and prospective evaluations (data not presented).
A median of 6 months (range: 2-26 months) elapsed from the date that planning for an evaluation began until the release of the evaluation report.
The reference laboratory evaluations were used to select rapid tests or testing algorithms for further evaluation in the field in eight countries and for implementation without a field evaluation in three countries (Botswana, Kenya, and Rwanda). After the reference laboratory evaluations, the majority of countries also began to procure rapid tests and to plan for the incorporation of rapid testing into VCT, prevention of mother-tochild-transmission (PMTCT), or other programs.
Field evaluations (Phase 2)
Evaluation methods. Between 2000 and 2004, eight countries (Angola, Côte d'Ivoire, Ethiopia, Mozambique, Namibia, Senegal, Tanzania, and Zimbabwe) conducted field evaluations of rapid tests before national implementation, but data from these evaluations were not available for Angola, Senegal, or Tanzania. In each evaluation, two to four (median: three) rapid tests were evaluated at two or three POS sites including VCT centers, blood donation centers, hospitals, or clinics. On-site PLATE 1494 Evaluation outcomes. Each field evaluation tested a median of 566 (range: 209-3791) specimens, of which a median of 28% (range: 13-81%) was HIV positive. Median sensitivity of the four rapid tests ranged from 99.4% to 100%. Median specificity ranged from 99.5% to 100%. Three of the four tests demonstrated a sensitivity or specificity below 99% in at least one evaluation.
Among countries that conducted both a reference laboratory evaluation and a field evaluation, a median of 29 (range: 12-42) months elapsed from the time of initial planning until completion of the evaluation report.
Implementation and quality assurance (Phase 3)
Based on the evaluation results, 10 of the 11 countries in our assessment adopted a standard, recommended rapid HIV testing algorithm (Table 3) . Nine different rapid tests were selected for use in rapid testing algorithms. Botswana, Kenya, Namibia, and Zimbabwe adopted parallel rapid testing algorithms. Angola, Côte d'Ivoire, Ethiopia, Mozambique, Rwanda, and Senegal adopted serial rapid testing algorithms. In six countries, a third "tiebreaker" test is used on-site if the results of the first two tests are discordant. In Angola and Mozambique, persons whose two screening tests are discordant are asked to return for retesting in 1 month; in CÙte d'Ivoire and Senegal, discordant specimens are sent to the national reference laboratory for resolution with more specific tests.
As of April, 2004, the recommended rapid testing algorithms had been implemented in over 350 VCT centers and approximately 120 PMTCT sites. The rapid testing algorithms are used for clinical HIV diagnosis, screening blood donors, testing prisoners, testing source patients after needle stick injuries in hospitals, and HIV surveillance. 
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Quality assurance methods
To help ensure the quality of rapid HIV testing, six countries (Botswana, Côte d'Ivoire, Kenya, Mozambique, Rwanda, and Zimbabwe) conduct regular retesting of a proportion of specimens at a reference laboratory (Namibia also adopted this process after data collection was completed for this assessment). In these countries, 5-10% of all HIV-positive and HIV-negative specimens are sent to a reference laboratory on an ongoing basis for retesting. In addition, at new VCT sites in Côte d'Ivoire, Kenya, and Mozambique, the first 150-500 clients are tested with both the standard HIV testing algorithm as well as the new rapid testing algorithm. In four countries, personnel from the ministry of health or reference laboratory periodically visit testing sites to observe testing practices and provide technical support. Ethiopia and Zimbabwe also implemented a proficiency panel testing program. In Zimbabwe, for example, a panel of three specimens is distributed monthly to 92 participating sites including hospital and private laboratories, VCT sites, and PMTCT sites. In addition to sample retesting and proficiency testing, a third indicator of the performance of a rapid testing algorithm is the rate of discordance between the two screening tests. WHO guidelines suggest that the discordance rate should not exceed 5%. 7 In four countries in which program data were available (Botswana, Côte d'Ivoire, Kenya, and Mozambique), the discordance rate between screening tests ranged from 0.4-1.1%.
Quality assurance outcomes
DISCUSSION
A significant challenge to scaling-up HIV prevention and care services in resource-poor countries is ensuring accurate, high-quality HIV testing, particularly as the number of testing sites increases. Challenges to achieving this include the limited human and technical resources, as well as concerns about the sensitivity of rapid tests in the face of the significant genetic diversity of HIV-1 subtypes in Africa. Our results indicate that rapid HIV tests provide reliable results in Africa and that a systematic approach to their evaluation and implementation resulted in reliable, decentralized HIV testing even when conducted by persons with limited laboratory experience.
Our assessment can provide only general information regarding the sensitivity of rapid HIV tests for the different HIV-1 subtypes, since we do not have information on the distribution of subtypes in the serum panels that were tested. Furthermore, the evaluations were conducted in laboratories with varying levels of sophistication and used different testing algorithms for the gold standard, making comparisons difficult. However, the 11 countries that conducted evaluations include most of the known HIV-1 subtypes in Africa. 16 The median PLATE 1496 sensitivity and specificity of rapid tests in most of the in-country evaluations were equivalent to or higher than published results from independent evaluations, 11, 17 and of the nine tests that were evaluated in more than one country, six had median sensitivities greater than 99%. Despite the great variability in laboratories and testing protocols, the evaluations yielded surprisingly similar results. For tests with more than one reference laboratory evaluation result, there was a median of only 2 percentage points (range: 0.5-4.8 percentage points) difference in the sensitivity between the best and worst evaluation result and a median of 0.7 percentage points (range: 0.3-4.3 percentage points) for specificity. Some of this variability may be explained by the small sample sizes in some of the evaluations, differences in storage conditions for test kits and specimens, and inclusion of weak positive specimens in some specimen panels but not others. Other factors, including transcription errors, may also have influenced the results. To help laboratory personnel assess whether their results are comparable to those of other evaluations, a central repository of evaluation results should be created. This repository, which should be easily accessible (e.g. located on the World Wide Web), would be a useful resource for persons selecting rapid tests for in-country evaluation, comparing performance in various settings, or designing evaluations.
Reference laboratory evaluations are resource and time intensive. The evaluations described in this report required a median of 6 months to complete and in one country more than 2 years. Including a field trial, the evaluation process may be expected to take at least 1 year. Evaluations were delayed by a variety of factors including difficulty in obtaining supplies, lack of staff, absence of laboratory information systems, and delays in obtaining ethical approval. Often, the planning and reporting stages were more time consuming than the actual laboratory testing. In countries under pressure to implement testing, this process can seem unnecessary. However, the experience in the countries where these evaluations were conducted was that they built familiarity and expertise with rapid tests, helped to overcome initial skepticism concerning test performance, raised interest in and awareness among stakeholders, and established methods (and specimen panels) for evaluating new rapid tests in the future. Reference laboratory evaluations can also help detect changes in test performance due to manufacturing problems. For example, sensitivity below expected levels for one rapid test led to the identification of a manufacturing defect that was subsequently corrected.
In many countries, the evaluations described in this report were the first ever conducted. Future evaluations may require less time as the staff have gained experience, and serum panels developed for these evaluations could be used in the future to assess newly introduced tests. The finding that the results of evaluations conducted on stored specimens were similar to those using prospectively collected specimens is reassuring to laboratory experts planning to use an established serum panel for multiple evaluations.
In a number of countries in our review, field evaluations were performed following the reference laboratory evaluations. The field evaluations replicated the conditions under which testing would occur at POS sites by using whole blood specimens that were collected prospectively. One limitation of the evaluations was that testing at the evaluation sites was performed by laboratory technicians; in reality, testing at many POS sites is performed by trained counselors. Nonetheless, the field evaluations provided further assurance that the tests performed adequately at the POS sites, and allowed personnel at the sites to gain familiarity with rapid tests and to adapt their counseling and testing procedures to incorporate rapid testing.
Among the countries in our review, the accuracy of rapid tests was similar in reference laboratory and field evaluations. This suggests that field evaluations may not require large numbers of specimens collected over long periods of time to demonstrate accuracy. This phase was important at a time when sites had little experience in rapid testing, and may not be necessary for introducing new tests at sites already conducting rapid testing.
Decentralization of testing presents many important challenges. These include the need to train counselors, nurses, laboratory technicians, and other personnel in the use of a variety of rapid tests and in pretest and posttest counseling. One of the most important barriers to this decentralization is the resistance to, and, in some countries, prohibition of, -HIV testing by nonlaboratory personnel. In Zimbabwe for example, until recently national policy mandated that HIV testing could be performed only by trained laboratory technicians. Following an evaluation that demonstrated the ability of trained nurse counselors to correctly perform rapid HIV testing in the absence of supervision from laboratory technicians, 18 a new policy was adopted that allowed nonlaboratory personnel to be trained and certified to perform rapid HIV testing. A similar evaluation of VCT counselors in Botswana demonstrated that concordance among rapid tests in the algorithm was equivalent whether testing was performed by laboratory or nonlaboratory personnel. 19 Quality assurance data from our study provide additional evidence that rapid testing conducted by nonlaboratory personnel was reliable. Reference laboratory retesting data from four countries showed a median concordance of 98.7% between the results of on-site rapid testing and reference laboratory retesting. For rapid test-positive specimens, concordance with reference laboratory retesting was exceptionally high (above 99%) in the most recent data from two countries and was below 90% in two countries. In Rwanda, additional on-site training was provided in response to the discrepant results found upon reference laboratory retesting of samples. However, we did not systematically collect information about each country's programmatic responses to the quality assurance results. The reasons for the incorrect rapid test results at POS sites are not known with certainty. There was anecdotal evidence that some of the errors were administrative including specimen mix-up and transcription errors. In addition, administrative errors during the retesting process itself could lead to incorrect measurement of rapid test performance. Lastly, when retesting programs identify specimens with discordant test results, it may be unclear whether the on-site rapid testing algorithm or the reference laboratory gold standard algorithm produced the correct result. Different rapid tests, EIAs, and Western blot tests vary in their sensitivity for early infection in recent seroconverters.
As countries scale up the number of testing sites, assuring quality testing will be an ever-increasing challenge. For example, rapid testing volume in Botswana increased from 3764 clients in 3 VCT centers in 2000 to 50,017 clients in 16 centers in 2003. During this same period, the rate of discordance
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among rapid tests within the algorithm gradually increased from 0.1% to 0.9%, suggesting a reduction in the quality of testing. Because Botswana implemented a parallel testing algorithm, results that were false positive by the first test in the algorithm were presumably detected by the second test. This important advantage of parallel algorithms is counterbalanced by their higher cost (since each sample is tested with at least two tests). In fact, two countries in our assessment originally selected parallel algorithms but later switched to serial algorithms to save reagent costs. The fact that four countries in our review implemented rapid testing without implementing systematic retesting of samples tested at POS and only two countries had a proficiency testing program highlights the need for more efforts to strengthen quality assurance procedures in countries implementing rapid HIV testing programs.
In our assessment, rapid HIV tests provided accurate results in laboratory-based evaluations, field evaluations, and POS testing. Furthermore, the use of a structured evaluation approach resulted in the selection of appropriate rapid HIV testing algorithms and helped to ensure the quality of HIV testing in the face of wide-scale implementation.
